Cargando…

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants

The emergence and global spread of the SARS-CoV-2 Omicron variants, which carry an unprecedented number of mutations, raise serious concerns due to the reduced efficacy of current vaccines and resistance to therapeutic antibodies. Here, we report the generation and characterization of two potent hum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhaochun, Zhang, Peng, Matsuoka, Yumiko, Tsybovsky, Yaroslav, West, Kamille, Santos, Celia, Boyd, Lisa F., Nguyen, Hanh, Pomerenke, Anna, Stephens, Tyler, Olia, Adam S., Zhang, Baoshan, De Giorgi, Valeria, Holbrook, Michael R., Gross, Robin, Postnikova, Elena, Garza, Nicole L., Johnson, Reed F., Margulies, David H., Kwong, Peter D., Alter, Harvey J., Buchholz, Ursula J., Lusso, Paolo, Farci, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554601/ https://www.ncbi.nlm.nih.gov/pubmed/36302375 http://dx.doi.org/10.1016/j.celrep.2022.111528

Ejemplares similares

Continued Complexity of Mutations in Omicron Sublineages
por: Spratt, Austin N., et al.
Publicado: (2022)

Distinct Cytokine Profiles Correlate with Disease Severity and Outcome in Longitudinal Studies of Acute Hepatitis B Virus and Hepatitis D Virus Infection in Chimpanzees
por: Engle, Ronald E., et al.
Publicado: (2020)

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
por: Andrade-Molina, D.A., et al.
Publicado: (2023)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages
por: Wang, Yuliang, et al.
Publicado: (2023)

Rapid emergence of omicron sublineages expressing spike protein R346T
por: Groenheit, Ramona, et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
por: Park, Young-Jun, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart
por: Girardi, Viviane, et al.
Publicado: (2023)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures
por: Dhawan, Manish, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
por: Wang, Yizhen, et al.
Publicado: (2023)

Change over Time in the Risk of Death among Japanese COVID-19 Cases Caused by the Omicron Variant Depending on Prevalence of Sublineages
por: Takahashi, Yuki, et al.
Publicado: (2023)

Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data
por: Hirotsu, Yosuke, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2023)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
por: Relan, Pryanka, et al.
Publicado: (2023)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
por: Li, Qianqian, et al.
Publicado: (2022)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Reduced COVID-19 morbidity and mortality in hemodialysis patients across the various Omicron sublineages—A retrospective analysis
por: Schuller, Max, et al.
Publicado: (2023)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022
por: Hirotsu, Yosuke, et al.
Publicado: (2022)

Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection
por: De Giorgi, Valeria, et al.
Publicado: (2021)

Novel Human Metapneumovirus Sublineage
por: Huck, Barbara, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_8tf69mnhk78mkn2k51nd7kpp37